Table 1. Details of the included studies.

Study	Location	Reference standard	Index test	Specimen	Sample size	Study design	Patient population
Poovorawari et al 1994 [23]	Thailand	ELISA 2nd, RIBA	Spot	Serum	192	Case-control	Hospital samples
Mvere et al 1996 [24]	Zimbabwe	EIA 2nd, INNO-LIA HCV Ab III	Spot	Serum	206	Cross-sectional	Blood bank
Montebugnoli et al 1999 [25]	Italy	ELISA (Ortho HCV 3.0), RIBA	Rapid	Whole blood	100	Case-control	Hospital samples
Kaur et al 2000 [26]	India	EIA 3rd	BiDot	Serum	2754	Cross-sectional	Hospital samples
Buti et al 2000 [27]	Spain	Immunometric technique, RIBA	Multiplo	Serum	188	Case-control	Hospital samples
Yuen et al 2001 [28]	China	EIA, PCR	SM-HCV	Serum	290	Case-control	Hospital samples
WHO 2001 [29]	Switzerland	ELISA, RIBA, PCR	α	Serum	257	Case-control	WHO panel
WHO 2001 [30]	Switzerland	ELISA, RIBA, PCR	TriDot 4th, Genedia	Serum	257	Case-control	WHO panel
WHO 2002 [31]	Switzerland	ELISA, RIBA, PCR	SDBioline	Serum	257	Case-control	Asia, Africa, Latin America & Europe
Hui et al 2002 [32]	Hong Kong	EIA	SM-HCV	Whole blood	197	Case-control	Hepatology clinic
Daniel et al 2005 [33]	India	EIA, RIBA, PCR	TriDot	Serum	2590	Cross-sectional	Outpatient /hepatology
Scheiblauer et al 2006 [12]	USA	EIA, PCR	β	Serum	381	Case-control	ICBS panel
Njouom et al 2006 [34]	Cameroon	EIA 3rd, PCR	ImmunocombHexagon	Plasma	329	Case-control	NK
Torane et al 2006 [35]	India	ELISA	Spot	Whole blood	60	Case-control	Blood banks
Nyirenda et al 2008 [36]	Malawi	ELISA, CLIA, Lineimmunoassay	Spot	Serum	202	Cross-sectional	Outpatient clinics
Ivantes et al 2010 [37]	Brazil	CLIA	Bioeasy	Whole blood	71	Cross-sectional	General population
Lee et al 2010 [38]	USA	EIA, RIBA	OraQuick	£	572	Cross-sectional	Low-risk persons
Lee et al 2011 [39]	USA	EIA, RIBA, PCR	OraQuick	£	2176	Case-control	Medical clinics
Smith et al 2011 [40]	USA	CLIA, RIBA	¥	Serum	1081	Cross-sectional	Injection drug users
Smith et al 2011 [41]	USA	MEIA/EIA/CLIA, RIBA	¥	Whole blood, Oral fluid	μ	Cross-sectional	Injection drug users
Drobnik et al 2011 [42]	USA	EIA, RIBA	OraQuick	Oral fluid	484	Cross-sectional	High-risk groups
Cha et al 2012 [43]	Korea	EIA	OraQuick	Oral fluid Serum	437	Case-control	Hospital samples
Maity et al 2012 [44]	India	ELISA	TriDot	Serum	300	Case-control	NK
Jewett et al 2012 [45]	USA	ELISA, RIBA, PCR	Chembio, Multiplo	Blood	406	Case-control	Injection drug users
Kant et al 2012 [46]	Germany	Architect HCV	Onsite	Serum	185	Case-control	Hospital samples
Kim et al 2013 [47]	Korea	ADVIA Centaur RIBA	SDBioline Genedia	Serum	100	Case control	Hospital samples
Al-Tahish et al 2013 [48]	Egypt	ELISA 3rd, HCV RNA	One-step TriDot 4th Immunocomb	Serum	100	Case-control	Blood donors
da Rosa et al 2013 [49]	Brazil	Architect HCV test, PCR	Bioeasy	Serum	307	Case-control	Hepatology clinic
O'Connell et al 2013 [50]	USA	ELISA 3rd	€	Plasma	674	Case-control	Blood banks
Tagny et al 2014 [51]	Cameron	ELISA	Hexagon	Plasma	1998	Cross-sectional	Blood banks

NK = not known. α = Advanced, TriDot, Serodia, Spot, SeroCard. β = Acon, HepaScan, TriDot, Genedia, i+Lab, Dipstick, Assure, SPAN, ImmunoRAPIDO. ¥ = Chembio, Multiplo, OraQuick. € = OraQuick, Instant, Axiom, FirstVue. μ = 197, 282, 389, 285, 432, 265, 266. £ = Oral fluid, whole blood, finger stick, plasma, serum.